Premium
Procollagen‐3 N ‐terminal peptide measurements for the detection of liver fibrosis in methotrexate‐treated patients with psoriasis: daily practice use and clinical implications
Author(s) -
Reek J.M.P.A.,
Menting S.P.,
Janssen W.W.L.,
Dhaliwal R.,
Heijboer A.C.,
Herwaarden A.E.,
Sweep F.C.G.J.,
Jong L.M.,
Tjwa E.T.,
Otero M.E.,
Spuls P.I.,
Jong E.M.G.J.
Publication year - 2017
Publication title -
british journal of dermatology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.304
H-Index - 179
eISSN - 1365-2133
pISSN - 0007-0963
DOI - 10.1111/bjd.15313
Subject(s) - methotrexate , psoriasis , medicine , procollagen peptidase , fibrosis , incidence (geometry) , liver fibrosis , gastroenterology , hepatic fibrosis , liver disease , dermatology , physics , optics
In the past, a varying incidence of liver fibrosis, which was attributed to methotrexate (MTX) treatment for psoriasis, has been reported.(1-5) However, recent reports show lower incidences of liver fibrosis in this group, and a low or absent risk attributable to MTX.(6,7) Dawwas et al. found that end-stage liver disease related to MTX was very uncommon (0.07% of 158 904 liver transplant patients), and that features of the metabolic syndrome were prevalent in those affected.(6) This article is protected by copyright. All rights reserve